Xeris Biopharma Holdings Inc [NASDAQ: XERS] gained 9.55% on the last trading session, reaching $4.13 price per share at the time.
If compared to the average trading volume of 1.59M shares, XERS reached a trading volume of 9558497 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Xeris Biopharma Holdings Inc [XERS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XERS shares is $4.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XERS stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Xeris Biopharma Holdings Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 11, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on March 28, 2024, representing the official price target for Xeris Biopharma Holdings Inc stock. Previously, the target price had yet another raise to $4.50, while Craig Hallum analysts kept a Buy rating on XERS stock.
The Average True Range (ATR) for Xeris Biopharma Holdings Inc is set at 0.22, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 3.29.
Trading performance analysis for XERS stock
Xeris Biopharma Holdings Inc [XERS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.84. With this latest performance, XERS shares gained by 13.46% in over the last four-week period, additionally plugging by 59.46% over the last 6 months – not to mention a rise of 35.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 67.82, with the RSI for the last a single of trading hit 71.81, and the three-weeks RSI is set at 65.04 for Xeris Biopharma Holdings Inc [XERS]. The present Moving Average for the last 50 days of trading for this stock 3.56, while it was recorded at 3.83 for the last single week of trading, and 2.93 for the last 200 days.
Xeris Biopharma Holdings Inc [XERS]: A deeper dive into fundamental analysis
Xeris Biopharma Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.29 and a Current Ratio set at 1.79.
An analysis of Institutional ownership at Xeris Biopharma Holdings Inc [XERS]
The top three institutional holders of XERS stocks are: BLACKROCK INC. with ownership of 10.33 million shares, which is approximately 7.3531%. VANGUARD GROUP INC, holding 7.66 million shares of the stock with an approximate value of $$17.23 million in XERS stocks shares; and VANGUARD GROUP INC, currently with $$11.51 million in XERS stock with ownership which is approximately 3.4469%.
